Svenska                Glossary                Search    
 
 
AboutTechnologyProjectInvestorMedia Releases 2012Contact
 
 
 
bg_ml_2012-06-18.png

   
Latest News Upcoming Events
   
   
February 4, 2013
Newron together with NeuroNova receives €2.5m Strategic Translation Award from Wellcome Trust to develop experimental drug candidate for ALS
December 17, 2012
Newron closes acquisition of NeuroNova
 


   
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Sitemap   Site policy
Site last updated: Wednesday 8 May 2013  
 
 
Project Pipeline

Project

    Indication  

Pre-clin.

   IND  

 Phase I/II

 Phase II

 Phase III 

sNN0029ALS      
sNN0031Parkinson's disease     
More about our ProjectsImage

 Business Development

NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.Image